Electroconvulsive therapy-specific volume changes in nuclei of the amygdala and their relationship to long-term anxiety improvement in depression.

Publication date: Jun 01, 2025

Electroconvulsive therapy (ECT) is one of the most effective treatments for depression. ECT induces volume changes in the amygdala, a key center of anxiety. However, the clinical relevance of ECT-induced changes in amygdala volume remains uncertain. We hypothesized that nuclei-specific amygdala volumes and anxiety symptoms in depression could explain the clinical correlates of ECT-induced volume changes. To test this hypothesis, we enrolled patients with depression who underwent ECT (N = 20) in this multicenter observational study and collected MRI data at three time points: before and after treatment and a 6-month follow-up. Patients who received medication (N = 52), cognitive behavioral therapy (N = 63), or transcranial magnetic stimulation (N = 20), and healthy participants (N = 147) were included for comparison. Amygdala nuclei were identified using FreeSurfer and clustered into three subdivisions to enhance reliability and interpretability. Anxiety symptoms were quantified using the anxiety factor scores derived from the Hamilton Depression Rating Scale. Before treatment, basolateral and basomedial subdivisions of the right amygdala were smaller than those of healthy controls. The volumes of the amygdala subdivisions increased after ECT and decreased during the follow-up period, but the volumes at 6-month follow-up were larger than those observed before treatment. These volume changes were specific to ECT. Long-term volume changes in the right basomedial amygdala correlated with improvements in anxiety symptoms. Baseline volumes in the right basolateral amygdala correlated with long-term improvements in anxiety symptoms. These findings demonstrate that clinical correlates of ECT-induced amygdala volume changes are existent, but in a nucleus and symptom-specific manner.

Open Access PDF

Concepts Keywords
Amygdala Adult
Freesurfer Aged
Increased Amygdala
Month Anxiety
Psychiatry Cognitive Behavioral Therapy
Depression
Depressive Disorder, Major
Electroconvulsive Therapy
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Transcranial Magnetic Stimulation
Treatment Outcome

Semantics

Type Source Name
disease MESH anxiety
disease MESH depression
disease MESH clinical relevance
disease MESH treatment resistant depression
drug DRUGBANK Tilmicosin
disease MESH edema
drug DRUGBANK Coenzyme M
disease MESH anhedonia
drug DRUGBANK Aminolevulinic acid
disease MESH Mood Disorders
drug DRUGBANK Methionine
disease MESH major depressive disorder
disease MESH depressive disorder
drug DRUGBANK Ethanol
disease MESH suicidal ideation
disease MESH suicide
disease MESH dementia
drug DRUGBANK Propofol
drug DRUGBANK Ketamine
drug DRUGBANK Sevoflurane
drug DRUGBANK Flunarizine
disease MESH Relapse
disease MESH seizure
drug DRUGBANK Trestolone
disease MESH privacy
disease MESH mental disorders
drug DRUGBANK L-Aspartic Acid
pathway REACTOME Immune System
disease MESH inflammation
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH anxiety disorder
drug DRUGBANK Hydrocortisone
pathway REACTOME Reproduction

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *